rs876661174
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PM2PM5PP3_ModeratePP5
The ENST00000234420.11(MSH6):c.3947G>A(p.Gly1316Glu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G1316R) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000234420.11 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MSH6 | NM_000179.3 | c.3947G>A | p.Gly1316Glu | missense_variant | 9/10 | ENST00000234420.11 | NP_000170.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MSH6 | ENST00000234420.11 | c.3947G>A | p.Gly1316Glu | missense_variant | 9/10 | 1 | NM_000179.3 | ENSP00000234420 | P4 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 35
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Pathogenic:1Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Jan 03, 2022 | This missense variant replaces glycine with glutamic acid at codon 1316 of the MSH6 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with colorectal cancer with tumors showing microsatellite instability and loss of MSH6 expression (PMID: 24100870). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | May 07, 2018 | The p.G1316E variant (also known as c.3947G>A), located in coding exon 9 of the MSH6 gene, results from a G to A substitution at nucleotide position 3947. The glycine at codon 1316 is replaced by glutamic acid, an amino acid with similar properties. This alteration was identified once in a study of MSH6 germline variants from a cohort of 1720 colon cancer patients. The patient had colon cancer at age 49 and her tumor was MSI-H. Also, immunohistochemistry (IHC) revealed absent MSH6 staining in her tumor and MLH1 promoter hypermethylation as well as BRAF analyses were negative (Terui H et al. Oncol. Rep., 2013 Dec;30:2909-16). This alteration was also identified as somatic in a MSI-H colon tumor that displayed loss of MSH6 staining on IHC (Ambry internal data). Based on an internal structural assessment, this alteration results in disruption of the C-terminal MSH2-MSH6 interface (Warren JJ et al. Mol. Cell, 2007 May;26:579-92). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD) (Lek M et al. Nature, 2016 08;536:285-91). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. In addition, the CoDP in silico tool predicts this alteration to likely impair molecular function, with a score of 0.999 (Terui H et al. J. Biomed. Sci. 2013 Apr;20:25). Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Hereditary nonpolyposis colorectal neoplasms Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 07, 2018 | This variant has been observed in an individual affected with colorectal cancer (PMID: 24100870). ClinVar contains an entry for this variant (Variation ID: 490016). This variant is not present in population databases (ExAC no frequency). This sequence change replaces glycine with glutamic acid at codon 1316 of the MSH6 protein (p.Gly1316Glu). The glycine residue is moderately conserved and there is a moderate physicochemical difference between glycine and glutamic acid. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant disrupts the p.Gly1316 amino acid residue in MSH6. Other variant(s) that disrupt this residue have been observed in affected individuals (PMID: 24440087), which suggests that this may be a clinically significant amino acid residue. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C15"). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at